Michael Higgins
Stock Analyst at Ladenburg Thalmann
(1.89)
# 2,882
Out of 4,829 analysts
19
Total ratings
33.33%
Success rate
5.24%
Average return
Main Sectors:
Stocks Rated by Michael Higgins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Downgrades: Neutral | n/a | $13.02 | - | 4 | May 9, 2024 | |
| FBRX Forte Biosciences | Upgrades: Buy | $69 | $6.23 | +1,002.79% | 3 | Apr 8, 2024 | |
| OVID Ovid Therapeutics | Reiterates: Buy | $7 | $0.29 | +2,291.53% | 1 | May 2, 2023 | |
| SCYX SCYNEXIS | Reiterates: Buy | $15 | $0.95 | +1,472.33% | 1 | Apr 3, 2023 | |
| RYTM Rhythm Pharmaceuticals | Reiterates: Buy | $35 | $59.22 | -40.90% | 3 | Mar 2, 2023 | |
| PHGE BiomX | Maintains: Buy | $130 → $80 | $0.53 | +15,014.30% | 2 | May 12, 2022 | |
| NVAX Novavax | Downgrades: Sell | $105 | $6.07 | +1,629.82% | 2 | Aug 5, 2020 | |
| VIRT Virtu Financial | Upgrades: Buy | $29 | $42.52 | -31.80% | 2 | Jan 4, 2019 | |
| SVRA Savara | Reinstates: Buy | n/a | $3.01 | - | 1 | Sep 27, 2017 |
Viridian Therapeutics
May 9, 2024
Downgrades: Neutral
Price Target: n/a
Current: $13.02
Upside: -
Forte Biosciences
Apr 8, 2024
Upgrades: Buy
Price Target: $69
Current: $6.23
Upside: +1,002.79%
Ovid Therapeutics
May 2, 2023
Reiterates: Buy
Price Target: $7
Current: $0.29
Upside: +2,291.53%
SCYNEXIS
Apr 3, 2023
Reiterates: Buy
Price Target: $15
Current: $0.95
Upside: +1,472.33%
Rhythm Pharmaceuticals
Mar 2, 2023
Reiterates: Buy
Price Target: $35
Current: $59.22
Upside: -40.90%
BiomX
May 12, 2022
Maintains: Buy
Price Target: $130 → $80
Current: $0.53
Upside: +15,014.30%
Novavax
Aug 5, 2020
Downgrades: Sell
Price Target: $105
Current: $6.07
Upside: +1,629.82%
Virtu Financial
Jan 4, 2019
Upgrades: Buy
Price Target: $29
Current: $42.52
Upside: -31.80%
Savara
Sep 27, 2017
Reinstates: Buy
Price Target: n/a
Current: $3.01
Upside: -